Ribociclib (LEE011) Rollover Study for Continued Access (NCT02934568)
An Open-label, Multi-center Rollover Protocol for Patients Who Have Participated in a Novartis-sponsored Ribociclib (LEE011) Study and Are Continuing to Benefit From Ribociclib as Single Agent or in Combination With Other Investigational Treatments
🩺 Plain-English Summary (8th-Grade Level)
This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-sponsored ribociclib (LEE011) study that has reached its primary objective(s) or has been halted for other reasons.
Who can join: Review the eligibility criteria below.
Location: University Of Alabama At Birmingham — Birmingham, Alabama
Age range: 0 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- University Of Alabama At Birmingham — Birmingham, Alabama
- Dana Farber Cancer Institute — Boston, Massachusetts
- The Regents of the Uni of Michigan — Ann Arbor, Michigan
- Broome Oncology — Johnson City, New York
- St Jude Childrens Research Hospital — Memphis, Tennessee
- Novartis Investigative Site — Lyon,
- Novartis Investigative Site — Villejuif,
- Novartis Investigative Site — Cologne, North Rhine-Westphalia
- Novartis Investigative Site — Singapore,
- Novartis Investigative Site — Madrid,
- Novartis Investigative Site — Madrid,
- Novartis Investigative Site — Tainan,
- Novartis Investigative Site — Taipei,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.